TABLE 1.
Staphylococcus aureus strains and plasmids used in this study
| Strain or plasmid | Relevant characteristic(s) | Vancomycin MIC (μg/ml) |
Reference(s) |
|---|---|---|---|
| 300-169 | PBa -MRSA, agr-I SCCmec IV CC45b | 0.5 | 5 |
| 301-188 | RBa -MRSA, agr-I SCCmec IV CC45 | 0.5 | 5 |
| 300-169p | 300-169 with pALC1766 | 0.5 | 13 |
| 301-188p | 301-188 with pALC1766 | 0.5 | 13 |
| 301-188p::ϕSA169 | 301-188 lysogenized with bacteriophage ϕSA169 and transduced with pALC1766 | 0.5 | This study |
| RN4220 | NCTC8325-4, α-hemolysin negative, β-hemolysin positive | 5 | |
| SH1000 | rsbU-positive derivative of NCTC8325-4, agr-I | 5 | |
| SH1001 | SH1000 agr::tet(M) Tetr | 5 | |
| pALC1766 | Derivative of pALC1484 in which the cap5 promoter was cloned upstream of gfpUVR reporter, Chlr | 13 |
PB, persistent MRSA bacteremia strain; RB, resolving MRSA bacteremia strain.
CC, clonal complex.